Skip to content
Clinical Trials – home

Age-related macular degeneration Basic Information

6 / 10 trials open to patients16 countries

In short

Age-related macular degeneration is a condition that gradually changes the way you see the world around you, affecting the central part of your vision while leaving your side vision intact. It's one of the most common causes of vision loss in older adults, and understanding it can help you take steps to protect your sight.

Key points

  • Nearly 20 million Americans have some form of AMD, making it the leading cause of vision loss in people over 60, yet early stages produce no symptoms at all.
  • AMD affects only central vision, leaving peripheral vision intact—meaning you won't go completely blind from this condition.
  • Age is the strongest risk factor, with risk jumping from 2% for those aged 50-59 to nearly 30% for those over 75.
  • Smoking is one of the few controllable risk factors—quitting significantly reduces your risk and can slow progression.
  • Straight lines appearing wavy is a critical warning sign that requires immediate attention from an eye doctor.
  • Regular eye exams after age 55 are crucial since early AMD can only be detected by a professional, not by symptoms you notice yourself.
  • Diet matters: leafy greens, omega-3-rich fish, and colorful fruits may help protect your eyes as you age.
  • Wet AMD accounts for only 10% of cases but causes much faster vision loss than dry AMD—though it can be treated with eye injections if caught early.

Who Is at Higher Risk?

Age stands as the strongest risk factor for developing AMD. People aged 55 and older are more likely to have the condition. However, several other factors can increase your chances of developing macular degeneration, even if you're not yet in the highest-risk age group.

Family history plays a significant role. If you have close relatives who have had AMD, your risk increases. This genetic connection means that if your parents or siblings have experienced vision loss from macular degeneration, you should be especially vigilant about getting regular eye examinations.

Race and ethnicity matter in AMD risk. Caucasian individuals face a higher risk compared to people of African, Hispanic, or Asian descent. The reasons for these differences are not completely understood, but the pattern is consistent across multiple studies.

Smoking cigarettes significantly increases your risk of developing AMD. In fact, smoking is one of the leading controllable risk factors for the disease. The harmful effects of tobacco on eye health are well-documented, making smoking cessation one of the most important preventive steps you can take.

Cardiovascular health connects to eye health in important ways. Having high blood pressure (hypertension) or high cholesterol levels can increase your risk. These conditions affect blood flow throughout the body, including the delicate blood vessels in the eyes.

Being overweight or having a higher body mass index (BMI) has been identified as a possible risk factor. Weight management, therefore, may play a role in protecting your vision as you age. Similarly, a diet high in saturated fats may increase risk, while a diet low in certain nutrients like fish, lutein, and zeaxanthin could leave your eyes more vulnerable.

Women may face a slightly higher risk than men, though this remains a possible rather than confirmed risk factor. Other factors that researchers continue to study include far-sightedness, exposure to sunlight, light-colored irises, cardiovascular disease, and lower levels of education.

Recognizing the Symptoms

Understanding the symptoms of AMD is crucial because early detection can make a significant difference in managing the condition. However, one of the most challenging aspects of early AMD is that it often produces no symptoms at all. This silent beginning means you could have the disease for a long time without noticing any changes in your vision.

Dry AMD progresses through three stages—early, intermediate, and late—and symptoms typically worsen over time. In the early stage, you won't notice any vision problems. During this phase, only an eye doctor can detect the condition through a comprehensive examination. This is why regular eye exams become so important as you age, even when your vision seems fine.

As dry AMD advances to the intermediate stage, some people still experience no symptoms. Others begin to notice mild changes, such as slight blurriness in their central vision or increased difficulty seeing in low lighting conditions. You might find yourself needing brighter lights for reading or noticing that it takes longer for your eyes to adjust when moving from bright to dim environments.

Late AMD, whether dry or wet, brings more noticeable and troubling symptoms. Many people observe that straight lines begin to look wavy or crooked. This distortion is a warning sign that should prompt immediate contact with your eye doctor. You might notice this while looking at doorframes, telephone poles, or the edges of buildings.

A blurry area may appear near the center of your vision. Over time, this blurry spot can grow larger, or you may develop blank spots or dark areas in your central vision. Imagine trying to read a book but finding that the words in the middle of the page seem to disappear or become impossible to make out, while you can still see the edges of the page clearly.

Colors may appear less bright or intense than they once did. You might notice that the vibrant colors you remember seem duller or washed out. Low lighting becomes increasingly problematic, making evening activities or poorly lit spaces more challenging to navigate.

Wet AMD tends to cause symptoms more suddenly than dry AMD. You might experience a rapid decrease in visual sharpness or the sudden appearance of blind spots in your central vision. The distortion of straight lines is particularly characteristic of wet AMD, as the fluid leaking from abnormal blood vessels causes the macula's structure to warp.

Despite these central vision problems, your peripheral vision—your ability to see things off to the sides—typically remains intact. This means you won't go completely blind from AMD. You'll still be able to see movement and shapes around you, which helps maintain some level of independence and spatial awareness.

Prevention Strategies

While there's no guaranteed way to prevent AMD, you can take several steps to reduce your risk or slow the progression if you're already showing early signs. These preventive measures focus on lifestyle choices and health management that support overall eye health.

Getting regular eye examinations is perhaps the most important preventive step you can take. Since early AMD produces no symptoms, the only way to catch it is through professional screening. If you're 55 or older, or if you have risk factors like family history, ask your doctor how often you should schedule eye exams. Don't wait for your vision to change before seeking care.

Quitting smoking stands out as one of the most effective ways to protect your vision. Smoking is a leading risk factor for AMD, and stopping can significantly reduce your chances of developing the disease or slow its progression if you already have it. The benefits of quitting extend beyond your eyes to your entire body.

Managing your blood pressure and cholesterol levels helps protect the blood vessels in your eyes. Work with your healthcare provider to keep these numbers in a healthy range through medication, if needed, and lifestyle modifications. Regular exercise, stress management, and following prescribed treatments all contribute to better cardiovascular health.

Diet plays a significant role in eye health. Eating a healthy diet rich in leafy green vegetables like broccoli and spinach, along with fish high in omega-3 fatty acids, can support retinal function. Colorful fruits and vegetables provide important nutrients that may help slow AMD progression. Consider incorporating foods like carrots, which have long been associated with good eye health, into your regular meals.

Maintaining a healthy weight matters for eye health just as it does for overall health. If you're overweight, working toward a healthier weight through balanced eating and regular physical activity may reduce your AMD risk.

Protecting your eyes from ultraviolet (UV) rays is another preventive measure. Wearing sunglasses that block harmful UV rays when outdoors shields your eyes from unnecessary stress. Make it a habit to wear protective eyewear consistently, not just on bright sunny days.

For people with intermediate dry AMD, specific dietary supplements may help. Your eye doctor might recommend a special combination of vitamins and minerals based on the AREDS2 formula, which includes vitamins C and E, zinc, copper, lutein, and zeaxanthin. Clinical trials have shown that this formula can decrease the risk of losing central vision and may slow the development of wet AMD. However, always talk to your doctor before starting any supplement regimen, as these are not appropriate for everyone.

How the Disease Changes Your Eyes

Understanding what happens inside your eyes when you have AMD can help you grasp why the symptoms occur and why early intervention matters. The disease involves physical and structural changes to the delicate tissues at the back of your eye.

Your macula sits at the center of your retina and measures only about 5 millimeters across. Despite its small size, this tiny area is responsible for all your detailed, straight-ahead vision. The macula contains special light-sensitive cells called photoreceptors that translate light into the electrical signals your brain interprets as images.

In dry AMD, the changes begin with the formation of drusen beneath the retina. These pale yellow deposits are made of proteins and fats. While a few small drusen are common as people age and don't necessarily cause problems, an accumulation of larger drusen is a hallmark of AMD. As these deposits build up, the macula begins to thin and waste away, a process called atrophy.

The advanced form of dry AMD is called geographic atrophy, where significant areas of the retina develop sharp-bordered zones of atrophy or wasting. In these areas, the light-sensitive cells have died off, creating permanent blind spots in your central vision. The process typically occurs gradually over several years.

Wet AMD involves a different set of changes. The hallmark of this form is choroidal neovascularization, a term that describes the growth of abnormal blood vessels beneath the retina. These vessels shouldn't be there, and they're structurally weak. They leak blood and fluid into the spaces around the retina, causing the retina's normal architecture to become distorted.

The leaked fluid creates a bulge in the macula, pushing it out of its normal position. This physical distortion is what causes straight lines to appear wavy. If left untreated, the abnormal blood vessels can form scar tissue that permanently replaces the normal retinal tissue, leading to irreversible loss of central vision.

Any stage of dry AMD can transform into wet AMD, though this happens in only about 10% of cases. When it does occur, the transition typically brings faster and more severe vision loss. However, wet AMD is always considered a late-stage form of the disease.

The progression of AMD affects not just the structure of your eye but also your body's inflammatory response. Inflammation in the eye appears to play a role in the disease process, particularly in the development of geographic atrophy. This understanding has led researchers to explore treatments that target inflammation as a way to slow disease progression.

Did you know?

  1. The global cost of visual impairment due to AMD is estimated at $343 billion, with $255 billion in direct healthcare costs alone, making it one of the most expensive eye conditions worldwide.
  2. While AMD affects central vision, it leaves peripheral vision completely intact, meaning people with advanced AMD can navigate their environment using their side vision, which is why they maintain independence longer than those with other causes of blindness.
  3. Dry AMD can suddenly transform into wet AMD at any stage, though only about 10% of dry AMD cases make this transition—but when they do, vision loss accelerates dramatically from years to potentially just weeks.

Questions people often ask

This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.

Clinical trials for Age-related macular degeneration

Recruiting trials first

See all 10 trials →
Quick filters

10 clinical trials in this condition

Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Eyebiotech Limited
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Eyebiotech Limited
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ranibizumab
  • Sponsor:F. Hoffmann-La Roche AG
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Medical University Of Vienna
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cemdisiran
  • Sponsor:Regeneron Pharmaceuticals Inc.
Countries:FranceFrance
  • Participants:65+ years
  • Sponsor:PulseSight Therapeutics
See all 10 trials →filters applied: condition = Age-related macular degeneration

Related conditions in the same therapeutic area

Back to all diseases
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).